KR930702002A - 아폽토시스 조정제 - Google Patents
아폽토시스 조정제Info
- Publication number
- KR930702002A KR930702002A KR1019930700644A KR930700644A KR930702002A KR 930702002 A KR930702002 A KR 930702002A KR 1019930700644 A KR1019930700644 A KR 1019930700644A KR 930700644 A KR930700644 A KR 930700644A KR 930702002 A KR930702002 A KR 930702002A
- Authority
- KR
- South Korea
- Prior art keywords
- combination
- effective amount
- acceptable carrier
- compound
- pharmacologically acceptable
- Prior art date
Links
- 229940076005 apoptosis modulator Drugs 0.000 title claims abstract 3
- 125000005606 carbostyryl group Chemical group 0.000 claims abstract 3
- 239000004480 active ingredient Substances 0.000 claims abstract 2
- 150000003839 salts Chemical class 0.000 claims abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims 7
- 239000003814 drug Substances 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000008506 pathogenesis Effects 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 206010043554 thrombocytopenia Diseases 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 abstract description 2
- 239000003607 modifier Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
본 발명의 목적은 아폽토시스 조정제를 제공하는데 있다. 본 발명에 따르면, 활성 성분으로서 하기 일반식(1)의 하나이상의 카르보스티릴 유도체 및 이의 염을 함유하는 아폽토시스 조정제가 제공된다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 약리시험예 1에 따른 아폽토시스 조정효과의 시험에서의 DNA단편화를 보여준다, 제2도는 약리시험예 5에 따른 M12 흑색종 세포 성장 억제의 결과를 보여주는 그래프이다, 제3도는 약리시험예 8에 따라 얻어진 자기면역 질병에 대한 생명-연장 효과의 결과를 보여주는 그래프이다.
Claims (11)
- 활성 성분으로서, 하기 일반식(1)의 하나 이상의 카르보스티릴 유도체 및 이의 염의 유효량을 약리학적으로 허용되는 이의 담체와 배합되어 함유하는 아폽토시스(apoptosis)조정제 :
-
- (상기식에서, R은 페닐환상에 치환기로서 저급 알콕시기를 가질 수 있는 벤조일기이고 카르보스티릴 골격의 3 및 4위치의 탄소-탄소결합은 단일결합 또는 이중결합이다).
- 제1항에서 정의한 하나 이상의 화합물의 유효량을 약리학적으로 허용되는 담체와 배합되어 함유하는 항암제.
- 제1항에서 정의한 하나 이상의 화합물의 유효량을 약리학적으로 허용되는 담체와 배합되어 함유하는 안티레트로바이로스제.
- 제1항에서 정의한 하나 이상의 화합물의 유효량을 약리학적으로 허용되는 담체와 배합되어 함유하는 자기 면역 질병에 대한 치료제.
- 제1항에서 정의한 하나 이상의 화합물의 유효량을 약리학적으로 허용되는 담체와 배합되어 함유하는 혈소판 감소중에 대한 치료제.
- 제1항에서 정의한 하나 이상의 화합물의 유효량을 약리학적으로 허용되는 담체와 배합되어 함유하는 알쯔하이며 질병에 대한 치료제.
- 제1항에서 정의한 하나 이상의 화합물의 유효량을 약리학적으로 허용되는 담체와 배합되어 함유하는 간장염에 대한 치료제.
- 제1항에서 정의한 하나 이상의 화합물의 유효량을 약리학적으로 허용되는 담체와 배합되어 함유하는 종양 병소전위 억제제.
- ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP16258791 | 1991-07-03 | ||
JP91-162587 | 1991-07-03 | ||
JP92-33469 | 1992-02-20 | ||
JP3346992 | 1992-02-20 | ||
JP92-45718 | 1992-03-03 | ||
JP4571892 | 1992-03-03 | ||
JP92-100585 | 1992-03-25 | ||
JP10058592 | 1992-03-25 | ||
PCT/JP1992/000841 WO1993000902A1 (en) | 1991-07-03 | 1992-07-02 | Apoptosis regulator |
Publications (2)
Publication Number | Publication Date |
---|---|
KR930702002A true KR930702002A (ko) | 1993-09-08 |
KR100196368B1 KR100196368B1 (ko) | 1999-06-15 |
Family
ID=27459795
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019930700644A KR100196368B1 (ko) | 1991-07-03 | 1992-07-02 | 아폽토시스 조정제 |
Country Status (12)
Country | Link |
---|---|
US (5) | US5672603A (ko) |
EP (1) | EP0552373B1 (ko) |
KR (1) | KR100196368B1 (ko) |
AU (1) | AU648690B2 (ko) |
CA (1) | CA2090876A1 (ko) |
DE (1) | DE69230131T2 (ko) |
DK (1) | DK0552373T3 (ko) |
ES (1) | ES2138971T3 (ko) |
HK (1) | HK1004469A1 (ko) |
MX (1) | MX9203950A (ko) |
TW (1) | TW229157B (ko) |
WO (1) | WO1993000902A1 (ko) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU666577B2 (en) * | 1992-08-19 | 1996-02-15 | Otsuka Pharmaceutical Co., Ltd. | Apoptosis regulator |
CA2134880A1 (en) * | 1993-03-02 | 1994-09-03 | Akira Matsumori | Graft rejection inhibitor and il-1 production inhibitor |
GB9311132D0 (en) * | 1993-05-28 | 1993-07-14 | Eisai London Res Lab Ltd | Control of cell death |
DK0674515T3 (da) * | 1993-10-21 | 1999-12-20 | Otsuka Pharma Co Ltd | Anvendelse af carbostyrilderivater til fremstilling af et medikament til inhibering af interleukin-8 |
US5504093A (en) * | 1994-08-01 | 1996-04-02 | Otsuka Pharmaceutical Co., Ltd. | Method for inhibiting nucleoside and nucleobase transport in mammalian cells, and method for inhibition of DNA virus replication |
WO1996021449A1 (en) * | 1995-01-11 | 1996-07-18 | Otsuka Pharmaceutical Co., Ltd. | Pharmaceutical composition of indene derivatives for regulating apoptosis |
WO1998046229A1 (fr) * | 1995-06-21 | 1998-10-22 | Otsuka Pharmaceutical Co., Ltd. | Inhibiteurs de la production d'il-8 et du mcaf |
JPH0971532A (ja) * | 1995-09-06 | 1997-03-18 | Otsuka Pharmaceut Co Ltd | 発癌抑制剤 |
US5700803A (en) * | 1995-12-12 | 1997-12-23 | Otsuka Pharmaceutical Co., Ltd. | Method for reducing infarct size in subjects afflicted with ischemic heart disease |
WO1998048807A1 (fr) * | 1997-04-25 | 1998-11-05 | Otsuka Pharmaceutical Co., Ltd. | Inhibiteurs de la synthese de l'hyaluronate |
US6008209A (en) * | 1997-04-28 | 1999-12-28 | Hoffmann-La Roche Inc. | Method of using vitamin D3 analogs with bis C-20 side chains |
WO1999015179A1 (en) * | 1997-09-25 | 1999-04-01 | Regents Of The University Of Minnesota | Methods of limiting apoptosis of cells |
US6281191B1 (en) | 1997-12-29 | 2001-08-28 | Vladimir I. Slesarev | Compositions and methods for treating hepatitis-C |
FR2774289B1 (fr) * | 1998-02-03 | 2002-05-24 | Goemar Lab Sa | Medicament pour le traitement des dereglements de l'apoptose |
IL140701A0 (en) | 1998-07-13 | 2002-02-10 | Univ Texas | Cancer treatment methods using antibodies to aminophospholipids |
SI1107795T1 (en) | 1998-09-04 | 2003-06-30 | The Regents Of The University Of Michigan | Thiomolybdate associated with at least one carbohydrate, and its use for preventing or treating diseases characterized by aberrant vascularization, such as cancer, wet type macular degeneration, rheumatoid arthritis |
US6277974B1 (en) | 1999-12-14 | 2001-08-21 | Cogent Neuroscience, Inc. | Compositions and methods for diagnosing and treating conditions, disorders, or diseases involving cell death |
US20030044413A1 (en) * | 2000-08-15 | 2003-03-06 | Regents Of The University Of Minnesota | Methods of limiting apoptosis of cells |
WO2003053222A2 (en) * | 2001-12-20 | 2003-07-03 | Cogent Neuroscience, Inc. | Methods for treating conditions, disorders, or diseases involving cell death |
ES2358730T3 (es) | 2002-07-15 | 2011-05-13 | Board Of Regents, The University Of Texas System | Anticuerpos seleccionados y péptidos de duramicina que se enlazan a fosfolípidos aniónicos y aminofosfolípidos y sus usos en el tratamiento de infecciones virales y del cáncer. |
EP1575578B1 (en) * | 2002-11-07 | 2009-12-09 | Regents Of The University Of Minnesota | Methods of treating injuries of the nervous system associated with hemorrhage |
US20060204481A1 (en) * | 2003-04-02 | 2006-09-14 | Steer Clifford J | Methods of promoting cell viability |
CN1953743B (zh) | 2004-01-22 | 2010-12-08 | 迈阿密大学 | 局部辅酶q10制剂及其使用方法 |
JP2008530100A (ja) * | 2005-02-10 | 2008-08-07 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | 視覚障害の治療方法 |
EP2136831B1 (en) | 2007-03-02 | 2012-09-12 | The Cleveland Clinic Foundation | Anti-angiogenic peptides |
ES2572356T3 (es) | 2007-11-09 | 2016-05-31 | Peregrine Pharmaceuticals Inc | Composiciones de anticuerpos dirigidos contra VEGF y procedimientos |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5430184A (en) * | 1977-08-10 | 1979-03-06 | Otsuka Pharmaceut Co Ltd | 3,4-dihydrocarbostyril derivative |
JPS6038384B2 (ja) * | 1978-03-24 | 1985-08-31 | 大塚製薬株式会社 | チオセミカルバゾン誘導体 |
JPS5777676A (en) * | 1980-10-31 | 1982-05-15 | Otsuka Pharmaceut Co Ltd | Carbostyril derivative |
JPS5793962A (en) * | 1980-12-01 | 1982-06-11 | Otsuka Pharmaceut Co Ltd | Carbostyryl derivative |
JPS62135423A (ja) * | 1985-12-09 | 1987-06-18 | Otsuka Pharmaceut Co Ltd | 低酸素症改善剤 |
-
1992
- 1992-07-02 AU AU22317/92A patent/AU648690B2/en not_active Ceased
- 1992-07-02 DE DE69230131T patent/DE69230131T2/de not_active Expired - Fee Related
- 1992-07-02 ES ES92914177T patent/ES2138971T3/es not_active Expired - Lifetime
- 1992-07-02 EP EP92914177A patent/EP0552373B1/en not_active Expired - Lifetime
- 1992-07-02 DK DK92914177T patent/DK0552373T3/da active
- 1992-07-02 KR KR1019930700644A patent/KR100196368B1/ko not_active IP Right Cessation
- 1992-07-02 CA CA002090876A patent/CA2090876A1/en not_active Abandoned
- 1992-07-02 WO PCT/JP1992/000841 patent/WO1993000902A1/ja active IP Right Grant
- 1992-07-03 MX MX9203950A patent/MX9203950A/es unknown
- 1992-07-15 TW TW081105603A patent/TW229157B/zh active
-
1995
- 1995-06-06 US US08/466,449 patent/US5672603A/en not_active Expired - Fee Related
-
1997
- 1997-05-09 US US08/854,073 patent/US5916890A/en not_active Expired - Fee Related
- 1997-05-09 US US08/854,074 patent/US5872120A/en not_active Expired - Fee Related
- 1997-05-09 US US08/853,745 patent/US5925640A/en not_active Expired - Fee Related
- 1997-05-09 US US08/853,746 patent/US5798358A/en not_active Expired - Fee Related
-
1998
- 1998-04-29 HK HK98103654A patent/HK1004469A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
EP0552373B1 (en) | 1999-10-13 |
US5925640A (en) | 1999-07-20 |
US5798358A (en) | 1998-08-25 |
CA2090876A1 (en) | 1993-01-04 |
DE69230131D1 (de) | 1999-11-18 |
HK1004469A1 (en) | 1998-11-27 |
KR100196368B1 (ko) | 1999-06-15 |
US5916890A (en) | 1999-06-29 |
TW229157B (ko) | 1994-09-01 |
EP0552373A1 (en) | 1993-07-28 |
WO1993000902A1 (en) | 1993-01-21 |
US5872120A (en) | 1999-02-16 |
AU2231792A (en) | 1993-02-11 |
AU648690B2 (en) | 1994-04-28 |
EP0552373A4 (en) | 1993-09-22 |
DE69230131T2 (de) | 2000-03-02 |
ES2138971T3 (es) | 2000-02-01 |
MX9203950A (es) | 1993-05-01 |
DK0552373T3 (da) | 1999-12-27 |
US5672603A (en) | 1997-09-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR930702002A (ko) | 아폽토시스 조정제 | |
ES2071621T3 (es) | Enantiomero dextrogiro del alfa-(tetrahidro-4,5,6,7-tieno-(3,2-c)-piridil-5)(cloro-2-fenil) acetato de metilo, su procedimiento de preparacion y las composiciones farmaceuticas que lo contienen. | |
KR930703303A (ko) | 1, 4-벤조티아제핀 유도체 | |
YU13695A (sh) | Upotreba 2-fenil-3-aroilbenzotiofena i njihove farmaceutske formulacije | |
NO963053D0 (no) | Kosmetiske eller farmasöytiske preparater inneholdende mangiferin eller derivater derav | |
KR950002755A (ko) | 워트마닌 및 그의 유사체에 의한 포스파티딜이노시톨 3-키나제의 억제 | |
RU95104885A (ru) | 1h-индол-3-глиоксиламиды, ингибирующие spla2-медируемое выделение жирных кислот, фармацевтическая композиция | |
CA2114156A1 (en) | Elucidation and Synthesis of Selected Pentapeptides | |
DE69705300T2 (de) | Cyclopropylalkansäurederivate | |
ES2178291T3 (es) | Uso de acidos 3-benzoil-aceticos, esteres, o amidas para el tratamiento del glaucoma glc1a. | |
BE901737A (fr) | Composition pharmaceutique pour le traitement de l'ischemie myocardique aigue. | |
ES2192234T3 (es) | Composiciones farmaceuticas parenterales conteniendo sales de amonioalquilo de acidos 2-arilpropionicos. | |
KR950703953A (ko) | 2-아미노-6-n-프로필아미노-4, 5, 6, 7-테트라하이드로벤조티아졸(프라미펙솔)의 항우울제로서의 용도(Use of 2-amino-6-n-propylamino-4, 5, 6, 7-tetrahydrobenzothiazole (pramipexol)as an antidepressant drug) | |
HUP0003571A2 (hu) | 6,9-Hídkötésű eritromicin-származékok | |
KR960006915A (ko) | 췌장염의 치료 조성물 | |
KR927003525A (ko) | 술폰아닐리드 유도체 및 의약 | |
KR950016760A (ko) | 치질 치료제 | |
KR910007531A (ko) | 15-케토-프로스타글란딘 화합물을 이용한 간 담즙성 질병의 치료 | |
ATE40987T1 (de) | Acetylenische phenoxypropanolderivate und pharmazeutische zusammensetzungen fuer die behandlung von bluthochdruck. | |
AR007297A1 (es) | Un compuesto derivado de 5-aroil-pirrol-2-ilmetilareno, medicamentos y composiciones farmaceuticas que lo contienen y usos del mismo. | |
BR9707770C1 (pt) | Tifluzamida com eficácia aperfeiçoada | |
SE9403137D0 (sv) | Derivatives of carbohydrates and compositions containing them | |
HUP9900504A2 (en) | Use of insect pheromones for producing pharmaceutical compositions having antiglucocorticoid effect | |
KR950016720A (ko) | 아밀로이드 단백질의 효과를 저해하는 방법 | |
KR910002792A (ko) | 1-치환된-2-(3-아미노-1-프로피닐)피롤리딘 유도체, 그에 의한 중추 콜린성 기능 장해 치료 방법 및 그로구성되는 제약학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
LAPS | Lapse due to unpaid annual fee |